| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by GCS.
Page 6: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1501 | 0 | 0 | 735 1980 TERATOLOGY 21(2):A72-A72 THEISEN CT THALIDOMIDE DYSMELIA - PROPOSED PATHOGENESIS | 0 | 1 |
| 1502 | 0 | 0 | 743 1981 ARCHIVES OF GYNECOLOGY 232(1-4):611-612 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL-ENDOCRINOLOGICAL STUDIES ON THALIDOMIDE-DAMAGED GIRLS | 1 | 1 |
| 1503 | 0 | 0 | 757 1981 LANCET 2(8242):368-368 MCBRIDE WG ANOTHER, LATE THALIDOMIDE ABNORMALITY | 1 | 1 |
| 1504 | 0 | 2 | 778 1982 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 32-2(8):898-898 FRANKUS E; FRIDERICHS E; GRAUDUMS I; HELM FC CHEMICAL-STRUCTURE, TERATOGENICITY AND PHARMACOLOGICAL ACTIVITY OF THALIDOMIDE RELATED-COMPOUNDS | 0 | 1 |
| 1505 | 0 | 0 | 782 1982 EEG-EMG-ZEITSCHRIFT FUR ELEKTROENZEPHALOGRAPHIE ELEKTROMYOGRAPHIE UND VERWANDTE GEBIETE 13(4):167-170 LUDOLPH A; MATZ DR ELECTRONEUROGRAPHIC STUDIES IN PATIENTS UNDER THALIDOMIDE THERAPY OF LUPUS ERYTHEMATODES DISCOIDES | 6 | 1 |
| 1506 | 0 | 0 | 811 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION - REPLY | 1 | 1 |
| 1507 | 1 | 5 | 814 1983 CLINICAL AND EXPERIMENTAL DERMATOLOGY 8(2):208-209 LAURET P THALIDOMIDE AND THE MANAGEMENT OF LUPUS-ERYTHEMATOSUS | 0 | 1 |
| 1508 | 0 | 0 | 817 1983 CLINICAL RESEARCH 31(5):A921-A921 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 1 | 1 |
| 1509 | 0 | 0 | 862 1984 TERATOLOGY 29(2):A19-A20 BRAUN AG; COLLINS M; HARDING F; WEINREB S FACTORS INFLUENCING THE ACTIVATION OF THALIDOMIDE TO A PRODUCT INHIBITING ATTACHMENT OF TUMOR-CELLS TO LECTIN COATED SURFACES | 0 | 1 |
| 1510 | 3 | 42 | 883 1985 EUROPEAN JOURNAL OF PHARMACOLOGY 119(1-2):39-46 YOUDIM MBH; ASHKENAZI R SEROTONERGIC INVOLVEMENT IN PHARMACOLOGICAL ACTION OF THE ANXIOLYTIC-SEDATIVES THALIDOMIDE AND SUPIDIMIDE | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1511 | 1 | 8 | 884 1985 EXPERIMENTAL ANIMALS 34(3):295-302 MATSUBARA Y; MIKAMI T TERATOGENIC POTENTIALITY OF SINGLE DOSE OF THALIDOMIDE IN JW-NIBS RABBITS | 0 | 1 |
| 1512 | 1 | 4 | 887 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(9):616-616 AYRES S DISCOID LUPUS-ERYTHEMATOSUS - THALIDOMIDE OR VITAMIN-E | 0 | 1 |
| 1513 | 1 | 2 | 895 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 BRODTHAGEN H SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 1 | 1 |
| 1514 | 2 | 3 | 896 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT - REPLY | 1 | 1 |
| 1515 | 5 | 8 | 900 1985 LANCET 2(8450):331-331 CRAWFORD CL THALIDOMIDE AND LEPROSY | 1 | 1 |
| 1516 | 0 | 0 | 908 1985 TERATOLOGY 31(3):A68-A68 TESH JM; NEWALL DR TERATOGENIC EFFECTS OF THALIDOMIDE ON RAT EMBRYOS INVITRO | 0 | 1 |
| 1517 | 2 | 3 | 925 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):283-283 MILLIKAN LE; HASTINGS RC THALIDOMIDE AND LYMPHOCYTE FUNCTION - REPLY | 0 | 1 |
| 1518 | 0 | 0 | 926 1986 LEPROSY REVIEW 57(1):76-77 LORETTI A; BARCHI E SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 1 |
| 1519 | 0 | 0 | 946 1987 JAPANESE JOURNAL OF PSYCHIATRY AND NEUROLOGY 41(2):197-206 KANNO O ELECTROENCEPHALOGRAPHIC STUDY OF 137 PATIENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 1 |
| 1520 | 0 | 0 | 950 1987 TERATOLOGY 35(2):A73-A73 HALES BF; JAIN R SPECIES-DIFFERENCES IN THE EFFECTS OF DRUG-METABOLIZING-ENZYMES ON THE TERATOGENICITY OF THALIDOMIDE IN RAT EMBRYO CULTURES | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1521 | 0 | 5 | 954 1988 ANAESTHESIA 43(7):613-614 MCCRORY JW ANESTHESIA AND THALIDOMIDE-RELATED ABNORMALITIES | 1 | 1 |
| 1522 | 6 | 11 | 988 1989 BIOCHEMICAL SOCIETY TRANSACTIONS 17(1):114-115 LYNE C; GOWER DB RADIAL THIN-LAYER CHROMATOGRAPHIC AUTORADIOGRAPHIC SCANS OF STEROID-METABOLISM IN THE PRESENCE OF THALIDOMIDE | 0 | 1 |
| 1523 | 0 | 0 | 1000 1989 MEDICINA CLINICA 92(15):571-571 CODINA C THALIDOMIDE 1989 | 1 | 1 |
| 1524 | 1 | 2 | 1030 1990 TERATOLOGY 41(2):239-239 MCCREDIE J PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY - COMMENT | 1 | 1 |
| 1525 | 0 | 0 | 1049 1991 MEDICINA CLINICA 97(2):79-79 TERCEDOR J; ORTEGO N; RODENAS JM; HERNANDEZ J TREATMENT OF RECURRENT APHTHAE WITH THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 1 | 1 |
| 1526 | 1 | 7 | 1050 1991 NEURO-OPHTHALMOLOGY 11(1):29-32 HUYGEN PLM; VANRIJN PM; VERHAGEN WIM; CREMERS CWRJ; THEUNISSEN EJJM SUBCORTICAL OPTOKINETIC RESPONSE IN A CASE OF THALIDOMIDE FETOPATHY | 0 | 1 |
| 1527 | 3 | 4 | 1092 1993 BRITISH MEDICAL JOURNAL 307(6909):939-940 BURROWS NP DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS - THALIDOMIDE MODIFIES DISEASE | 1 | 1 |
| 1528 | 0 | 0 | 1096 1993 CLINICAL RESEARCH 41(2):A496-A496 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 1 | 1 |
| 1529 | 3 | 10 | 1105 1993 MEDICINA CLINICA 101(4):158-158 PIZARRO A; PINILLA J; GARCIATOBARUELA A THERAPY WITH THALIDOMIDE AND TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION | 0 | 1 |
| 1530 | 0 | 0 | 1123 1994 BLOOD 84(10):A431-A431 SCHLEGEL PG; FERNANDEZ LP; BAKER J; CHEN Y; CHAO NJ THALIDOMIDE DOES NOT MODULATE THE IL-2 RESPONSE OF ACTIVATED JURKAT CELLS AS MEASURED BY BETA-GAL-ACTIVITY AND BY IL-2 PRODUCTION | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1531 | 0 | 0 | 1157 1994 PANMINERVA MEDICA 36(1):44-47 VOSGERAU JCB ATYPICAL HERPES SIMPLE - A SIGN OF TOXOPLASMOSIS ACTIVITY IN AIDS PATIENTS AND THE USE OF THALIDOMIDE | 0 | 1 |
| 1532 | 5 | 6 | 1182 1995 CLINICAL AND EXPERIMENTAL DERMATOLOGY 20(1):85-85 MISERY L; PEGUETNAVARRO J; THIVOLET J; FAURE M; SCHMITT D; CLAUDY AL THALIDOMIDE DOES NOT AFFECT IN-VITRO MIXED SKIN CELL LYMPHOCYTE REACTIONS | 0 | 1 |
| 1533 | 1 | 1 | 1193 1995 EXPERIMENTAL HEMATOLOGY 23(12):1324-1324 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION (VOL 23, PG 978, 1995) | 1 | 1 |
| 1534 | 0 | 0 | 1218 1995 NEUROLOGY 45(4):A168-A168 CLAVELOU P; COLAMARINO R; DINCAN M; DEFFOND D; TOURNILHAC M; SOUTEYRAND P THALIDOMIDE-RELATED NEUROPATHY - A PROSPECTIVE, CLINICAL, ELECTROMYOGRAPHIC TRIAL | 1 | 1 |
| 1535 | 2 | 3 | 1220 1995 PRESSE MEDICALE 24(1):40-40 COUDERC LJ; MATHEZ D; LEIBOWITCH J; AUTRAN B; CAUBARRERE I PROLONGED THALIDOMIDE TREATMENT IN AN HIV-INFECTED PATIENT | 0 | 1 |
| 1536 | 0 | 0 | 1229 1996 AMERICAN JOURNAL OF EPIDEMIOLOGY 143(11):6-6 Yang Q; Khoury MJ; James LM; Olney RS; Paulozzi LJ The return of thalidomide? Are birth defects surveillance systems ready? | 0 | 1 |
| 1537 | 0 | 0 | 1241 1996 ARTHRITIS AND RHEUMATISM 39(9):1352-1352 Stevens RJ; Andujar C; Edwards C; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. | 0 | 1 |
| 1538 | 0 | 0 | 1243 1996 ARTHRITIS AND RHEUMATISM 39(9):1524-1524 Lee S; Klausner J; Oliver S; Kaplan G; McCullagh E Treatment of rheumatoid arthritis (RA) with thalidomide | 1 | 1 |
| 1539 | 2 | 12 | 1256 1996 CLINICAL INFECTIOUS DISEASES 23(3):504-505 Levine AM Editorial response - Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 1 | 1 |
| 1540 | 1 | 5 | 1259 1996 ENDOSCOPY 28(5):471-472 Louvel D; Musso S; Metivier S; Croizet O; Rouquet RM; Massip P; Escourrou J; Frexinos J Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: Efficacy of thalidomide treatment | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1541 | 9 | 14 | 1263 1996 GASTROINTESTINAL ENDOSCOPY 44(6):729-731 Bellomo A; SchorrLesnick B Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV | 0 | 1 |
| 1542 | 4 | 5 | 1287 1996 NATURE MEDICINE 2(2):132-132 Crawford CL Thalidomide neuropathy | 1 | 1 |
| 1543 | 0 | 0 | 1311 1997 ANNALS OF INTERNAL MEDICINE 127(10):951-952 Vanchieri C Preparing for thalidomide's comeback | 1 | 1 |
| 1544 | 0 | 0 | 1320 1997 BRITISH MEDICAL JOURNAL 315(7110):699-699 Rutter T Thalidomide ban to be lifted in the US | 1 | 1 |
| 1545 | 18 | 27 | 1344 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
| 1546 | 0 | 1 | 1366 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
| 1547 | 0 | 0 | 1374 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
| 1548 | 0 | 0 | 1376 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
| 1549 | 0 | 0 | 1395 1998 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 55(17):1746-+ Kepple SR Thalidomide approval brings tight restrictions on access | 1 | 1 |
| 1550 | 0 | 0 | 1405 1998 ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1551 | 2 | 3 | 1421 1998 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
| 1552 | 11 | 23 | 1488 1999 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
| 1553 | 0 | 0 | 1504 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 1554 | 0 | 0 | 1506 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| 1555 | 0 | 0 | 1507 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| 1556 | 0 | 0 | 1508 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 1557 | 0 | 0 | 1511 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 1558 | 0 | 0 | 1514 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| 1559 | 6 | 10 | 1552 1999 INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
| 1560 | 0 | 0 | 1555 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1561 | 14 | 27 | 1557 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
| 1562 | 0 | 0 | 1577 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
| 1563 | 3 | 5 | 1625 2000 ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
| 1564 | 0 | 0 | 1644 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 1565 | 0 | 0 | 1646 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
| 1566 | 0 | 0 | 1657 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| 1567 | 0 | 0 | 1658 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
| 1568 | 0 | 0 | 1664 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
| 1569 | 0 | 0 | 1667 2000 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
| 1570 | 0 | 0 | 1672 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1571 | 6 | 16 | 1689 2000 CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 1572 | 2 | 2 | 1726 2000 INFLAMMATORY BOWEL DISEASES 6(2):152-153 Katz JA Thalidomide for Crohn's disease: High dose, low dose, or "no doze" at all? Comment | 1 | 1 |
| 1573 | 12 | 41 | 1749 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
| 1574 | 4 | 10 | 1760 2000 MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
| 1575 | 2 | 4 | 1781 2000 PALLIATIVE MEDICINE 14(5):429-431 Deaner PB The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report | 0 | 1 |
| 1576 | 0 | 68 | 1790 2000 SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| 1577 | 16 | 22 | 1792 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
| 1578 | 1 | 3 | 1794 2000 TERATOLOGY 62(3):172-173 Adams J; Buttar HS; Chambers C; Collins TFX; Graham JM; Jones KL; Kweder S; Mitala J; Polifka JE; Schwetz BA; Public Affairs Comm Teratology society public affairs committee position paper: Thalidomide | 0 | 1 |
| 1579 | 1 | 1 | 1812 2001 ANNALS OF ONCOLOGY 12(9):1333-1333 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001) | 0 | 1 |
| 1580 | 0 | 0 | 1816 2001 ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1581 | 2 | 4 | 1828 2001 BLOOD 97(8):2527-2528 Kyrtsonis MC; Kokoris SI; Kontopidou FN; Siakantaris MP; Kittas C; Pangalis GA Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody | 0 | 1 |
| 1582 | 0 | 0 | 1838 2001 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
| 1583 | 0 | 0 | 1846 2001 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
| 1584 | 0 | 0 | 1859 2001 BLOOD 98(11):309B-309B Kasper B; Moehler TM; Neben K; Ho AD; Goldschmidt H Response to a combination therapy of thalidomide and Pegintron (R) in patients with progressive multiple myeloma (MM). | 0 | 1 |
| 1585 | 0 | 0 | 1862 2001 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
| 1586 | 0 | 0 | 1867 2001 BLOOD 98(11):365B-365B Game M; Coso D; Sturgeon J; Crump M; Keating A Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). | 0 | 1 |
| 1587 | 0 | 0 | 1871 2001 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
| 1588 | 0 | 0 | 1872 2001 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
| 1589 | 0 | 0 | 1873 2001 BLOOD 98(11):775A-775A Mitsiades N; Mitsiades CS; Poulaki V; Akiyama M; Tai YT; Lin BK; Hayashi T; Catley L; Hideshima T; Chauhan D; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. | 0 | 1 |
| 1590 | 0 | 0 | 1876 2001 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1591 | 4 | 4 | 1880 2001 BONE MARROW TRANSPLANTATION 27(2):229-230 Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K Severe cutaneous ulceration following treatment with thalidomide for GVHD | 0 | 1 |
| 1592 | 30 | 32 | 1885 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
| 1593 | 3 | 8 | 1892 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):484-485 Biagi JJ; Prince HM Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation | 1 | 1 |
| 1594 | 1 | 2 | 1901 2001 CHEMISTRY IN BRITAIN 37(11):38-40 Stephens T Reinventing thalidomide | 0 | 1 |
| 1595 | 0 | 0 | 1939 2001 HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
| 1596 | 13 | 25 | 1952 2001 ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
| 1597 | 9 | 16 | 1996 2001 PEDIATRIC DERMATOLOGY 18(2):143-145 Brik R; Shamali H; Bergman R Successful thalidomide treatment of severe infantile Behcet disease | 1 | 1 |
| 1598 | 26 | 48 | 1999 2001 QUIMICA NOVA 24(5):683-688 Lima LM; Fraga CAM; Barreiro EJ The rebirth of a drug: Thalidomide | 0 | 1 |
| 1599 | 5 | 7 | 2003 2001 SCIENTIST 15(2):1-+ Lewis R The return of thalidomide | 0 | 1 |
| 1600 | 7 | 11 | 2017 2002 AIDS 16(17):2355-2356 Teo S; Noormohamed F; Youle M; Johnson M; Peters B; Stirling D; Thomas S Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1601 | 8 | 26 | 2020 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(12):2115-2122 Ginsburg PM; Ehrenpreis ED A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis | 0 | 1 |
| 1602 | 3 | 3 | 2024 2002 AMERICAN JOURNAL OF HEMATOLOGY 70(3):265-265 Pulik M; Genet P; Lionnet F; Touahri T Thalidomide-associated gynecomasty in a patient with multiple myeloma | 1 | 1 |
| 1603 | 18 | 27 | 2037 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
| 1604 | 0 | 0 | 2066 2002 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
| 1605 | 0 | 0 | 2068 2002 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
| 1606 | 0 | 0 | 2069 2002 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
| 1607 | 0 | 0 | 2077 2002 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
| 1608 | 0 | 0 | 2082 2002 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
| 1609 | 0 | 0 | 2087 2002 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
| 1610 | 0 | 0 | 2095 2002 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1611 | 0 | 0 | 2111 2002 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |
| 1612 | 0 | 0 | 2120 2002 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
| 1613 | 0 | 0 | 2121 2002 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
| 1614 | 0 | 0 | 2123 2002 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
| 1615 | 0 | 0 | 2124 2002 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
| 1616 | 4 | 4 | 2138 2002 BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
| 1617 | 11 | 23 | 2150 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 1 | 1 |
| 1618 | 14 | 18 | 2160 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
| 1619 | 17 | 34 | 2175 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
| 1620 | 0 | 0 | 2188 2002 FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1621 | 0 | 0 | 2189 2002 GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
| 1622 | 0 | 0 | 2193 2002 GUT 50:A4-A4 Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study | 1 | 1 |
| 1623 | 13 | 20 | 2197 2002 HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
| 1624 | 3 | 10 | 2200 2002 HAEMATOLOGICA 87(8):884-886 Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes | 1 | 1 |
| 1625 | 13 | 15 | 2203 2002 HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
| 1626 | 2 | 32 | 2239 2002 JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
| 1627 | 2 | 4 | 2263 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Crawford CL Thalidomide-induced neuropathy | 1 | 1 |
| 1628 | 4 | 6 | 2265 2002 MEDICAL JOURNAL OF AUSTRALIA 177(5):278-278 McBride W Thalidomide and cancer | 1 | 1 |
| 1629 | 1 | 1 | 2272 2002 ONCOLOGY-NEW YORK 16(1):21-22 Kurstin R Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease | 1 | 1 |
| 1630 | 53 | 61 | 2277 2002 ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1631 | 11 | 47 | 2282 2002 PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
| 1632 | 11 | 15 | 2285 2002 REVUE DE MEDECINE INTERNE 23(7):651-656 Claudon A; Dietemann JL; De Compte AH; Hassler P Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis. | 1 | 1 |
| 1633 | 8 | 31 | 2297 2003 ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
| 1634 | 11 | 28 | 2298 2003 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
| 1635 | 8 | 19 | 2316 2003 ANNALS OF PHARMACOTHERAPY 37(7-8):1040-1043 Kaur A; Yu SS; Lee AJ; Chiao TB Thalidomide-induced sinus bradycardia | 1 | 1 |
| 1636 | 156 | 187 | 2317 2003 ANNALS OF PHARMACOTHERAPY 37(9):1307-1320 Nasca MR; Micali G; Cheigh NH; West LE; West DP Dermatologic and nondermatologic uses of thalidomide | 1 | 1 |
| 1637 | 14 | 24 | 2321 2003 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
| 1638 | 13 | 26 | 2336 2003 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 13(20):3415-3417 Man HW; Corral LG; Stirling DI; Muller GW alpha-fluoro-substituted thalidomide analogues | 1 | 1 |
| 1639 | 0 | 0 | 2359 2003 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
| 1640 | 0 | 0 | 2375 2003 BLOOD 102(11):453A-453A Lacy MQ; Dispenzieri A; Gertz MA; Wilzig TE; Greipp PR; Fonseca R; Lust JA; Kumar S; Zeldenrust S; Kyle RA; Snow D; Hayman SR; Sidor CF; Treston AM; Zeldis JB; Rajkumar SV ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1641 | 13 | 35 | 2402 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 0 | 1 |
| 1642 | 11 | 28 | 2404 2003 BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| 1643 | 4 | 7 | 2416 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 1 | 1 |
| 1644 | 1 | 1 | 2421 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
| 1645 | 52 | 86 | 2443 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 0 | 1 |
| 1646 | 13 | 38 | 2444 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 1647 | 11 | 18 | 2446 2003 DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
| 1648 | 6 | 42 | 2448 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
| 1649 | 14 | 33 | 2453 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| 1650 | 4 | 10 | 2463 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1651 | 5 | 10 | 2465 2003 INTERNAL MEDICINE 42(7):605-608 Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis | 1 | 1 |
| 1652 | 6 | 40 | 2468 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 1 |
| 1653 | 6 | 15 | 2477 2003 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
| 1654 | 20 | 46 | 2488 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
| 1655 | 3 | 29 | 2495 2003 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
| 1656 | 19 | 32 | 2498 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
| 1657 | 6 | 10 | 2504 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 1 | 1 |
| 1658 | 3 | 20 | 2511 2003 LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
| 1659 | 0 | 0 | 2514 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 1660 | 5 | 8 | 2517 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1661 | 5 | 8 | 2518 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
| 1662 | 13 | 57 | 2523 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
| 1663 | 12 | 13 | 2524 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
| 1664 | 1 | 6 | 2525 2003 LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
| 1665 | 12 | 17 | 2527 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
| 1666 | 12 | 27 | 2530 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 0 | 1 |
| 1667 | 12 | 35 | 2536 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 1668 | 2 | 3 | 2539 2003 NEW ENGLAND JOURNAL OF MEDICINE 348(18):1821-1822 Morgan AE; Smith WK; Levenson JL Reversible dementia due to thalidomide therapy for multiple myeloma | 1 | 1 |
| 1669 | 3 | 31 | 2540 2003 ONCOLOGIST 8:39-45 Hussein MA Modifications to therapy for multiple myeloma: Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide | 0 | 1 |
| 1670 | 20 | 25 | 2543 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1671 | 11 | 22 | 2544 2003 PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS 33:15-18 Rodeghiero F; Elice F Thalidomide and thrombosis | 0 | 1 |
| 1672 | 77 | 104 | 2562 2003 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
| 1673 | 32 | 40 | 2598 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
| 1674 | 13 | 28 | 2606 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 1 | 1 |
| 1675 | 10 | 33 | 2607 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| 1676 | 6 | 23 | 2608 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| 1677 | 11 | 40 | 2656 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
| 1678 | 27 | 54 | 2657 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
| 1679 | 21 | 42 | 2667 2004 MAYO CLINIC PROCEEDINGS 79(7):883-889 Mesa RA; Elliott MA; Schroeder G; Tefferi A Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia | 1 | 1 |
| 1680 | 44 | 57 | 2676 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1681 | 8 | 10 | 2678 2004 NEUROLOGY 62(12):2288-2290 Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus | 1 | 1 |
| 1682 | 8 | 10 | 2679 2004 NEUROLOGY 62(12):2291-2293 Cavaletti G; Beronio A; Reni L; Ghiglione E; Schenone A; Briani C; Zara G; Cocito D; Isoardo G; Ciaramitaro P; Plasmati R; Pastorelli F; Frigo M; Piatti M; Carpo M Thalidomide sensory neurotoxicity - A clinical and neurophysiologic study | 1 | 1 |
| 1683 | 0 | 0 | 13 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY DM IS THALIDOMIDE TO BLAME | 0 | 0 |
| 1684 | 0 | 0 | 18 1961 BRITISH MEDICAL JOURNAL 2(524):125-& [Anon] PURPURA ASSOCIATED WITH THALIDOMIDE | 0 | 0 |
| 1685 | 0 | 0 | 19 1961 BRITISH MEDICAL JOURNAL 2(525):660-& LONGSTAFF JHL PURPURA ASSOCIATED WITH THALIDOMIDE | 0 | 0 |
| 1686 | 3 | 5 | 21 1961 BRITISH MEDICAL JOURNAL 2(525):876-& [Anon] THALIDOMIDE NEUROPATHY | 1 | 0 |
| 1687 | 0 | 0 | 46 1961 MEDICAL JOURNAL OF AUSTRALIA 1(23):868-& [Anon] THALIDOMIDE | 0 | 0 |
| 1688 | 0 | 0 | 47 1961 MEDICAL JOURNAL OF AUSTRALIA 2(24):966-& POOLE WG THALIDOMIDE | 0 | 0 |
| 1689 | 0 | 0 | 51 1962 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 84(7):979-& TAUSSIG HB PHOCOMELIA AND THALIDOMIDE | 0 | 0 |
| 1690 | 0 | 0 | 52 1962 AMERICAN ZOOLOGIST 2(4):559-559 SMITH TE; BERNDT WO; OLEARY JF; CAVANAUGH DJ THE INVITRO INHIBITORY EFFECT OF THALIDOMIDE ON THE CHICK EMBRYO | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1691 | 1 | 2 | 55 1962 BRITISH MEDICAL JOURNAL (5270):55-& SIMPSON JA MYXOEDEMA AFTER THALIDOMIDE (DISTAVAL) | 0 | 0 |
| 1692 | 4 | 6 | 56 1962 BRITISH MEDICAL JOURNAL (5276):477-& WILLMAN A; DUMOULIN JG THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 0 | 0 |
| 1693 | 1 | 3 | 57 1962 BRITISH MEDICAL JOURNAL (5276):477-& LILLICRAP DA MYXOEDEMA AFTER THALIDOMIDE (DISTAVAL) | 0 | 0 |
| 1694 | 0 | 0 | 58 1962 BRITISH MEDICAL JOURNAL (5280):792-& ROBERTSON WF THALIDOMIDE (DISTAVAL) AND VITAMIN-B DEFICIENCY | 0 | 0 |
| 1695 | 0 | 0 | 60 1962 BRITISH MEDICAL JOURNAL (5283):1025-& [Anon] PERIPHERAL NEURITIS DUE TO THALIDOMIDE | 0 | 0 |
| 1696 | 2 | 4 | 61 1962 BRITISH MEDICAL JOURNAL (5290):1469-& [Anon] THALIDOMIDE (DISTAVAL) IN MEDICINE CUPBOARDS | 0 | 0 |
| 1697 | 1 | 2 | 62 1962 BRITISH MEDICAL JOURNAL (5294):1758-& WIGGLESWORTH R; WRIGHT GB THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 0 | 0 |
| 1698 | 0 | 0 | 63 1962 BRITISH MEDICAL JOURNAL (5298):175-& [Anon] PROSTHESES FOR INFANTS WITH DEFORMITIES CAUSED BY THALIDOMIDE | 0 | 0 |
| 1699 | 0 | 0 | 64 1962 BRITISH MEDICAL JOURNAL (5299):236-& WOOLLAM DHM THALIDOMIDE DISASTER CONSIDERED AS AN EXPERIMENT IN MAMMALIAN TERATOLOGY | 0 | 0 |
| 1700 | 0 | 0 | 65 1962 BRITISH MEDICAL JOURNAL (5299):261-& WHITEFRA.A; RATTENBURY G HELP FOR THALIDOMIDE BABIES | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1701 | 6 | 8 | 66 1962 BRITISH MEDICAL JOURNAL (5300):306-& YORKE RA; KILSHAW D; TAYLOR WH; SUTTON WS NEUROPATHY, HYPOGLYCAEMIA, AND ADRENAL DYSFUNCTION DURING TREATMENT WITH THALIDOMIDE | 0 | 0 |
| 1702 | 0 | 0 | 67 1962 BRITISH MEDICAL JOURNAL (5303):522-& WHITEFRA.A THALIDOMIDE BABIES MEMORANDUM FROM BRITISH PAEDIATRIC ASSOCIATION | 0 | 0 |
| 1703 | 0 | 0 | 68 1962 BRITISH MEDICAL JOURNAL (5303):545-& APPLEBEY M HELP FOR THALIDOMIDE BABIES | 0 | 0 |
| 1704 | 2 | 3 | 70 1962 BRITISH MEDICAL JOURNAL (5305):647-& GILLIS L THALIDOMIDE BABIES - MANAGEMENT OF LIMB DEFECTS | 0 | 0 |
| 1705 | 0 | 6 | 71 1962 BRITISH MEDICAL JOURNAL (5305):672-& BASSIL GT; RIESS W; SCHMID K; KEBERLE H; FAIGLE JW THALIDOMIDE AND GLUTETHIMIDE | 0 | 0 |
| 1706 | 0 | 0 | 72 1962 BRITISH MEDICAL JOURNAL (5305):673-& CAPENER N THALIDOMIDE BABIES | 0 | 0 |
| 1707 | 0 | 0 | 73 1962 BRITISH MEDICAL JOURNAL (5307):785-& [Anon] PROPERTIES OF THALIDOMIDE | 0 | 0 |
| 1708 | 0 | 0 | 74 1962 BRITISH MEDICAL JOURNAL (5307):796-& SAUNDERS H; WRIGHT R; HODGKIN K THALIDOMIDE AND CONGENITAL DEFORMITIES | 0 | 0 |
| 1709 | 0 | 0 | 75 1962 BRITISH MEDICAL JOURNAL (5308):857-& CLAY AA DEFORMITIES NOT DUE TO THALIDOMIDE | 0 | 0 |
| 1710 | 1 | 1 | 77 1962 BRITISH MEDICAL JOURNAL (5311):1061-& RICEEDWARDS TJ; BELL R THALIDOMIDE AND MOUSE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1711 | 0 | 2 | 78 1962 BRITISH MEDICAL JOURNAL (5313):1176-& [Anon] CENSUS OF THALIDOMIDE BABIES | 0 | 0 |
| 1712 | 3 | 5 | 81 1962 BRITISH MEDICAL JOURNAL (5317):1447-& LECUTIER MA PHOCOMELIA AND INTERNAL DEFECTS DUE TO THALIDOMIDE | 0 | 0 |
| 1713 | 0 | 0 | 82 1962 BRITISH MEDICAL JOURNAL (5317):1462-& BURROWS HJ; RITCHIE T; WILSON K; SHARRARD WJ; CHAMBERLAIN R; SWETNAM; WIGGLESWORTH R; MCKENZIE DS; GILLIS L; JOLLY DW; WINNER A MANAGEMENT OF THALIDOMIDE DEFORMITIES | 0 | 0 |
| 1714 | 2 | 2 | 83 1962 BRITISH MEDICAL JOURNAL (5317):1476-& RICEEDWARDS JT THALIDOMIDE AND CANCER | 0 | 0 |
| 1715 | 9 | 13 | 85 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(10):462-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 1716 | 0 | 0 | 86 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(14):664-& [Anon] WITHDRAWAL OF THALIDOMIDE FROM MARKET | 0 | 0 |
| 1717 | 0 | 0 | 89 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(8):412-& [Anon] DISPOSAL OF SUPPLIES OF THALIDOMIDE | 0 | 0 |
| 1718 | 0 | 0 | 91 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(18):981-& THEORET JJ CHRONOLOGY OF THALIDOMIDE STORY | 0 | 0 |
| 1719 | 0 | 0 | 93 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(24):1293-& GILDER SSB THALIDOMIDE AND AFTER | 0 | 0 |
| 1720 | 0 | 0 | 94 1962 CIRCULATION 26(4):795-& TAUSSIG HB THALIDOMIDE AND PHOCOMELIA | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1721 | 0 | 0 | 98 1962 ECONOMIST 204(8):711-712 [Anon] AFTER THALIDOMIDE | 0 | 0 |
| 1722 | 0 | 0 | 99 1962 ECONOMIST 204(9):769-769 SWEETMAN WP AFTER THALIDOMIDE | 0 | 0 |
| 1723 | 1 | 1 | 103 1962 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 181(7):654-& YONKMAN FF THALIDOMIDE AND RELATED COMPOUNDS | 0 | 0 |
| 1724 | 0 | 0 | 104 1962 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 181(7):654-& TAUSSIG HB THALIDOMIDE AND RELATED COMPOUNDS - REPLY | 0 | 0 |
| 1725 | 6 | 8 | 107 1962 JOURNAL OF PEDIATRICS 61(1):158-& HECHT F THALIDOMIDE BABIES | 0 | 0 |
| 1726 | 6 | 8 | 118 1962 LANCET 1(7224):307-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 1727 | 0 | 0 | 121 1962 LANCET 1(7228):542-& OLIVER MY THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 0 |
| 1728 | 0 | 0 | 133 1962 LANCET 2(7248):195-& FRANKLIN AW; RATTENBURY G; HERFORD M; NETTELL A THALIDOMIDE-DAMAGED INFANTS | 0 | 0 |
| 1729 | 0 | 0 | 136 1962 LANCET 2(7250):297-& JACOBS J THALIDOMIDE DAMAGED INFANTS | 0 | 0 |
| 1730 | 0 | 1 | 138 1962 LANCET 2(7250):306-& [Anon] THALIDOMIDE BABIES | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1731 | 4 | 10 | 139 1962 LANCET 2(7251):336-& [Anon] THALIDOMIDE .2. | 0 | 0 |
| 1732 | 0 | 2 | 142 1962 LANCET 2(7253):452-& DIJKHUIS HJ; JONGE GAD; BEKKER BV; VANCREVELD S; MONCHY GD; GREENE R; HAGENBEE.JH THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 0 |
| 1733 | 0 | 0 | 150 1962 LANCET 2(7262):931-& [Anon] CONGENITAL ABNORMALITIES DUE TO THALIDOMIDE | 1 | 0 |
| 1734 | 0 | 0 | 152 1962 LANCET 2(7263):986-& [Anon] CONGENITAL ABNORMALITIES DUE TO THALIDOMIDE | 1 | 0 |
| 1735 | 5 | 35 | 153 1962 LANCET 2(7265):1095-& [Anon] THALIDOMIDE AND AFTER | 0 | 0 |
| 1736 | 0 | 0 | 155 1962 LANCET 2(7266):1162-& TRUETA J CARE OF THALIDOMIDE BABIES - EXPERIENCE IN GERMANY | 0 | 0 |
| 1737 | 0 | 0 | 158 1962 MEDICAL JOURNAL OF AUSTRALIA 1(14):533-& THOMPSON HL CONGENITAL ABNORMALITIES AND THALIDOMIDE | 0 | 0 |
| 1738 | 0 | 0 | 160 1962 MEDICAL JOURNAL OF AUSTRALIA 1(19):735-& PRYOR CH CONGENITAL ABNORMALITIES AND THALIDOMIDE | 0 | 0 |
| 1739 | 0 | 0 | 162 1962 MEDICAL JOURNAL OF AUSTRALIA 2(7):267-& [Anon] THALIDOMIDE SITUATION | 0 | 0 |
| 1740 | 0 | 0 | 163 1962 MEDICAL JOURNAL OF AUSTRALIA 2(7):273-& LOVELL R CONGENITAL ABNORMALITIES AND THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1741 | 0 | 0 | 164 1962 MEDICAL JOURNAL OF AUSTRALIA 2(14):567-& TUREK MA THALIDOMIDE SITUATION | 0 | 0 |
| 1742 | 0 | 0 | 165 1962 MEDICAL JOURNAL OF AUSTRALIA 2(17):677-& [Anon] CARE OF THALIDOMIDE BABIES | 0 | 0 |
| 1743 | 0 | 0 | 170 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(25):1320-& WHITEHILL LA THALIDOMIDE AND PHOCOMELIA | 0 | 0 |
| 1744 | 3 | 10 | 172 1962 PRESSE MEDICALE 70(31):1521-& TUCHMANNDUPLESSIS A PROPOS DES MALFORMATIONS ATTRIBUEES A UN SOMNIFERE LA THALIDOMIDE | 0 | 0 |
| 1745 | 1 | 14 | 176 1962 PUBLIC HEALTH REPORTS 77(11):946-946 [Anon] THALIDOMIDE | 0 | 0 |
| 1746 | 0 | 0 | 177 1962 ROYAL SOCIETY OF HEALTH JOURNAL 82(5):223-224 [Anon] THALIDOMIDE | 0 | 0 |
| 1747 | 0 | 0 | 178 1962 SCIENCE 137(3529):497-& WOLFLE D THALIDOMIDE LESSON | 0 | 0 |
| 1748 | 0 | 0 | 180 1963 ACTA PAEDIATRICA 52(6):619-& PLUM P THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1749 | 0 | 0 | 181 1963 ACTA PAEDIATRICA 52(6):627-& ROSENDAL T APLASIA AND HYPOPLASIA OF LABYRINTH FOLLOWING THALIDOMIDE | 0 | 0 |
| 1750 | 0 | 0 | 186 1963 ACTA PHYSIOLOGICA SCANDINAVICA 59:87-& LARSEN V TERATOGENIC EFFECTS OF THALIDOMIDE, IMIPRAMINE HCL AND IMIPRAMINE N-OXIDE HCL ON WHITE DANISH RABBITS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1751 | 7 | 41 | 188 1963 ARCHIVES FRANCAISES DE PEDIATRIE 20(10):1242-& RAVAILLE G; MAUER ML; METZ J PREMIER CAS DEMBRYOPATHIE A LA THALIDOMIDE ETUDIE EN FRANCE | 0 | 0 |
| 1752 | 0 | 1 | 191 1963 BIOCHEMICAL PHARMACOLOGY 12:246-& VASILESCU V; CIURES A; DIMOFTAC.C; TRUTIA E DES RESULTATS CONCERNANT LACTION DE LA THALIDOMIDE SUR LES ACIDES NUCLEIQUES | 0 | 0 |
| 1753 | 0 | 0 | 193 1963 BIOLOGICAL BULLETIN 125(2):373-& BURKE JA; SPEAR JF SOME MORPHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF THALIDOMIDE ON EMBRYOS OF FUNDULUS HETEROCLITUS | 0 | 0 |
| 1754 | 0 | 0 | 194 1963 BRITISH MEDICAL JOURNAL (532):123-& STEWART A CONGENITAL DEFECTS DUE TO THALIDOMIDE | 0 | 0 |
| 1755 | 0 | 0 | 195 1963 BRITISH MEDICAL JOURNAL (532):456-& [Anon] DERMATOGLYPHICS OF THALIDOMIDE BABIES | 0 | 0 |
| 1756 | 2 | 19 | 196 1963 BRITISH MEDICAL JOURNAL (533):610-& EVERED DF; RANDAL HG THALIDOMIDE AND B VITAMINS | 0 | 0 |
| 1757 | 0 | 1 | 197 1963 BRITISH MEDICAL JOURNAL (533):664-& [Anon] SEX RATIO OF THALIDOMIDE BABIES | 0 | 0 |
| 1758 | 0 | 0 | 198 1963 BRITISH MEDICAL JOURNAL (534):1333-& [Anon] CONTINUING EFFECT OF THALIDOMIDE | 0 | 0 |
| 1759 | 3 | 24 | 199 1963 BRITISH MEDICAL JOURNAL (536):973-& BUCKLE RM BLOOD PYRUVIC ACID IN THALIDOMIDE NEUROPATHY | 0 | 0 |
| 1760 | 1 | 3 | 200 1963 BRITISH MEDICAL JOURNAL (537):1527-& SIMPSON JA THALIDOMIDE NEUROPATHY | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1761 | 0 | 0 | 202 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(2):99-& JONG JDD THALIDOMIDE AND FUTURE CONTROL OF DRUGS | 0 | 0 |
| 1762 | 0 | 0 | 203 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(9):488-& [Anon] REHABILITATION OF THALIDOMIDE-DEFORMED CHILDREN | 0 | 0 |
| 1763 | 0 | 2 | 209 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 89(3):141-& GILDER SSB ECHOES OF THALIDOMIDE | 0 | 0 |
| 1764 | 0 | 0 | 212 1963 COLUMBIA JOURNALISM REVIEW 1(4):53-53 SILBER F MORE ON THALIDOMIDE | 0 | 0 |
| 1765 | 0 | 0 | 221 1963 JOURNAL OF ANATOMY 97(2):308-& METCALF WK THALIDOMIDE, NITRITE SENSITIVITY REACTION AND PYRIDOXINE | 0 | 0 |
| 1766 | 0 | 0 | 222 1963 JOURNAL OF ANATOMY 97(3):479-& METCALF WK THALIDOMIDE, NITRITE SENSITIVITY REACTION AND VITAMIN B COMPLEX | 0 | 0 |
| 1767 | 0 | 1 | 223 1963 JOURNAL OF ANATOMY 97(4):638-& METCALF WK METABOLIC DERIVATIVES OF THALIDOMIDE AND HAEMOGLOBIN NITRITE SENSITIVITY REACTION | 0 | 0 |
| 1768 | 0 | 0 | 228 1963 LANCET 1(727):501-& SWEETNAM WP THALIDOMIDE AND NEED TO LABEL DRUGS | 0 | 0 |
| 1769 | 0 | 0 | 231 1963 LANCET 1(728):553-& SAWISTOWSKA M THALIDOMIDE AND NEED TO LABEL DRUGS | 0 | 0 |
| 1770 | 0 | 1 | 240 1963 LANCET 1(729):1375-& DIJKHUIS HJ; VANDUYNE WM; BEKKER BV THALIDOMIDE AND CONGENTIAL ABNORMALITIES | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1771 | 0 | 0 | 252 1963 POULTRY SCIENCE 42(5):1257-& BOONE MA; HAMMOND M; BARNETT BD EFFECT OF THALIDOMIDE ON DOMESTIC FOWL | 2 | 0 |
| 1772 | 1 | 5 | 255 1963 PRESSE MEDICALE 71(45):2151-& PIZON P A PROPOS DES MALFORMATIONS PROVOQUEES PAR LA THALIDOMIDE | 0 | 0 |
| 1773 | 5 | 11 | 256 1963 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 112(4):1022-& POLKWILL.A; REUYLLUT.H; BLATTNER RJ ABNORMALITIES IN CHICK EMBRYOS FOLLOWING THALIDOMIDE AND OTHER INSOLUBLE COMPOUNDS IN AMNIOTIC CAVITY | 0 | 0 |
| 1774 | 0 | 0 | 263 1963 SOCIAL EDUCATION 27(3):131-133 WOODWORTH JR THALIDOMIDE IN RETROSPECT | 0 | 0 |
| 1775 | 9 | 12 | 264 1964 AMERICAN HEART JOURNAL 67(2):184-& MARTIN JK CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE + THEIR MANAGEMENT | 0 | 0 |
| 1776 | 0 | 0 | 268 1964 ANATOMICAL RECORD 148(2):375-& HAGEN EO CONGENITAL ANOMALIES OF LIMBS ASSOCIATED WITH MATERNAL INGESTION OF THALIDOMIDE | 0 | 0 |
| 1777 | 0 | 1 | 276 1964 BRITISH MEDICAL JOURNAL 1(539):1559-& LUTWAKMANN C THALIDOMIDE-TREATED MALE RABBITS | 0 | 0 |
| 1778 | 0 | 0 | 277 1964 BRITISH MEDICAL JOURNAL 2(541):679-& [Anon] ONCOLYTIC PROPERTIES OF THALIDOMIDE | 0 | 0 |
| 1779 | 0 | 0 | 282 1964 FEDERATION PROCEEDINGS 23(2P1):243-& FRIEDMAN L; SHUE GM; HOVE EL RESPONSE OF RATS TO THALIDOMIDE AS INFLUENCED BY RIBOFLAVIN DEFICIENCY | 0 | 0 |
| 1780 | 0 | 0 | 284 1964 JOURNAL OF ANIMAL SCIENCE 23(3):906-& GRAVES CN; SALISBURY GW; LODGE JR EFFECT OF THALIDOMIDE ON BOVINE SPERMATOZOAN METABOLISM | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1781 | 0 | 2 | 289 1964 LANCET 2(735):574-& [Anon] THALIDOMIDE | 0 | 0 |
| 1782 | 0 | 1 | 297 1964 NEW ENGLAND JOURNAL OF MEDICINE 271(18):963-& WHITEHILL LA; INGALLS TH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1783 | 0 | 0 | 306 1965 ACTA PAEDIATRICA SCANDINAVICA S:79-& DAVIGNON M; HELLGREN K; JUHLIN IM THALIDOMIDE DAMAGED CHILDREN EXPERIENCES FROM EUGENIAHEMMET | 0 | 0 |
| 1784 | 0 | 0 | 319 1965 BRITISH JOURNAL OF PREVENTIVE & SOCIAL MEDICINE 19(2):94-& OTTERLAN.A EFFECT OF THALIDOMIDE WARNING ON MEDICINE PRESCRIBED FOR PREGNANT WOMEN - ANALYSIS OF FREE MEDICINES DELIVERED TO EXPECTANT MOTHERS IN VASTERBOTTEN COUNTY OF SWEDEN DURING 1961 AND 1962 | 0 | 0 |
| 1785 | 0 | 0 | 325 1965 CANADIAN MEDICAL ASSOCIATION JOURNAL 92(11):585-& WEBB JF THALIDOMIDE PROBLEM IN CANADA | 0 | 0 |
| 1786 | 3 | 5 | 331 1965 COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES 159(5):1059-& CAHEN CRR; DUPUIS R MALFORMATIONS VISCERALES PROVOQUEES PAR LE THALIDOMIDE CHEZ LE LAPIN | 0 | 0 |
| 1787 | 0 | 3 | 340 1965 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 192(2):173-& APGAR V SEARCH FOR BIRTH DATA ON THALIDOMIDE-SENSITIVE PERIOD | 0 | 0 |
| 1788 | 0 | 0 | 341 1965 LANCET 2(7417):855-& MCBRIDE WG THALIDOMIDE | 0 | 0 |
| 1789 | 5 | 19 | 342 1965 LANCET 2(7421):1059-& [Anon] ANOTHER CHANCE FOR THALIDOMIDE | 7 | 0 |
| 1790 | 0 | 1 | 343 1965 LANCET 2(7421):1074-& SPEIRS AL THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1791 | 0 | 0 | 348 1965 PATHOLOGIE BIOLOGIE 13(11-1):709-& ROUX C; CAHEN R; DUPUIS R MALFORMATIONS VISCERALES PROVOQUEES PAR LE THALIDOMIDE CHEZ LE LAPIN | 0 | 0 |
| 1792 | 0 | 0 | 349 1965 PATHOLOGIE BIOLOGIE 13(23-2):1241-& CHAMPYHA.S LE GLUTARIMIDE ET LACTIVITE DE LA THALIDOMIDE . ETUDE SPECTRALE ETENDUE JUSQUE VERS 2050A | 0 | 0 |
| 1793 | 0 | 0 | 350 1965 POSTGRADUATE MEDICINE 38(4):A162-& [Anon] THALIDOMIDE LEGACY | 0 | 0 |
| 1794 | 5 | 11 | 361 1966 AMERICAN JOURNAL OF NURSING 66(9):2023-2026 SOULES BJ THALIDOMIDE VICTIMS IN A REHABILITATION CENTER | 0 | 0 |
| 1795 | 0 | 0 | 362 1966 AMERICAN JOURNAL OF OPHTHALMOLOGY 62(5):982-& RAFUSE E; ARSTIKAI.MJ EYE FINDINGS IN 20-THALIDOMIDE BABIES | 0 | 0 |
| 1796 | 0 | 0 | 364 1966 BRITISH MEDICAL JOURNAL 1(5479):92-& [Anon] THALIDOMIDE NEUROPATHY | 0 | 0 |
| 1797 | 1 | 1 | 365 1966 BRITISH MEDICAL JOURNAL 2(5510):400-& [Anon] THALIDOMIDE | 0 | 0 |
| 1798 | 14 | 28 | 366 1966 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE,USSR 61(2):185-& ALEKSAND.PN; BOGDANOV.VA; CHERNUKH AM TERATOGENIC EFFECT OF THALIDOMIDE IN EXPERIMENTS ON CHICK EMBRYOS | 0 | 0 |
| 1799 | 0 | 2 | 368 1966 CANADIAN MEDICAL ASSOCIATION JOURNAL 95(6):280-& GILDER SSB LONDON LETTER - LIVING OR DEAD - TREATMENT OF ACUTE LEUKEMIA IN ADULTS - THALIDOMIDE AND IMMUNOLOGY - DESCENDING PERINEUM - LOW INTELLIGENCE AND OBSTETERIC COMPLICATIONS | 0 | 0 |
| 1800 | 0 | 1 | 373 1966 DERMATOLOGICA 133(5):433-& HOGERZEI.LM; SIMONS RDG THALIDOMIDE-THERAPY IN ACUTE LEPROSY REACTIONS | 0 | 0 |
Page 6: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22